Skip to main content Accessibility help
×
Home

Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection*

  • Ulrich R. Hengge (a1), Mathias Baumann (a1), Rolf Maleba (a2), Norbert H. Brockmeyer (a1) and Manfred Goos (a1)...

Abstract

The effect of the testosterone derivative oxymetholone alone or in combination with the H1receptor antagonist ketotifen, which has recently been shown to block tumour necrosis factor α (TNFα), on weight gain and performance status in human immunodeficiency virus (HIV) patients with chronic cachexia was evaluated in a 30 week prospective pilot study. Thirty patients were randomly assigned to either oxymetholone monotherapy (n 14) or oxymetholone plus ketotifen (n 16). Patients receiving treatment were compared with a group of thirty untreated matched controls, who met the same inclusion criteria. Body weight and the Karnofsky index, which assessesthe ability to perform activities of daily life, and several quality-of-life variables were measured to evaluate response to therapy. The average weight gain at peak was 8. 2 (SD 6. 2) kg ( + 14. 5 % of body weight at study entry) in the oxymetholone group (P<0·0.001), and 6.1 (SD 4.6) kg (+ 10.9 %) in the combination group (P<0·005), compared with an average weight loss of 1.8 (SD 0.7) kg in the untreated controls. The mean time to peak weight was 196 weeks in the monotherapy group and 20.8 weeks in the combination group. The Karnofsky index improved equally in both groups from 56% before to 67% after 20 weeks of treatment (P< 0·05). The quality of life variables (activities of daily life, and appetite/nutrition) improved in 68 % (P<0·05)and 91%(P< 0·01) of the treated patients respectively. Oxymetholone was safe and promoted weight gain in cachectic patients with advanced HIV-1 infection. The addition of ketotifendid not further support weight gain. These results suggest the need for a randomized, double-blind, placebo-controlled multicentre trial.

Copyright

References

Hide All
Allen, B. J., Blagojevic, N., Delaney, I., Pollock, C. A., Ibels, L. S., Allman, M. A., Tiller, DJ., Gaskin, K. J., Baur, L. A., Waters, D. L., Cowell, C., Ambler, G., Quigley, C. & Fletcher, J. P. (1990). The role of body protein in clinical trials. In In Vivo Body Composition Studies, pp. 155169 [Yasumura, S., Harrison, J. E., McNeill, K. G., Woodhead, A. D. and Dilmanian, F. A., editors] New York: Plenum Press.
Arnold, A., Potts, G. O. & Beyler, A. L. (1963). Evaluation of the protein anabolic properties of certain orally active anabolic agents based on nitrogen balance studies in rats. Endocrinology 72, 408417.
Beisel, W. R., Edelmann, R., Nauss, K. & Suskind, R. M. (1981). Single-nutrient effects on immunologic functions. Journal of the American Medical Association 245, 5358.
Camerino, B. & Sala, G. (1960). Anabolic steroids. Progress in Drug Research 2, 71134.
Chandra, R. K. (1983). Nutrition, immunity, and infection: present knowledge and future directions. Lancet 1, 688691.
Coodley, G. O., Loveless, M. O., Nelson, H. D. & Coodley, M. K. (1994). Endocrine function in the HIV wasting syndrome. Journal of the Acquired Immune Deficiency Syndrome 7, 4651.
Dobs, A. S., Dempsey, M. A., Ladenson, P. W. & Polk, B. F. (1988). Endocrine disorders in men infected with the human immunodeficiency virus. American Journal of Medicine 84, 611616.
Doney, K., Pepe, M., Storb, R., Bryant, E., Anasetti, C., Appelbaum, F. R., Buckner, C. D. & Sanders, J. (1992). Immunosuppressive therapy of aplastic anemia: results of a prospective, randomized trial of antithymocyte globulin (ATG), methylprednisolone, and oxymetholone to ATG, very high methylprednisolone, and oxymetholone. Blood 79, 25662571.
Engelson, E. S., Pisunyer, F. X. & Kotler, D. P. (1995). Effects of megestrol acetate therapy on bodycomposition and circulating testosterone concentrations in patients with AIDS. AIDS 9, 11071108.
Escaich, S., Ritter, J., Rougier, P., Lepot, D., Lamelin, J. P., Sepetjan, M. & Trepo, C. (1991). Plasma viraemia as a marker of viral replication in HIV-infected individuals. AIDS 5, 1181194.
Forbes, G. B. (1985). The effect of anabolic steroids on lean body mass: the dose response curve. Metabolism 34, 571573.
Forbes, G. B., Porta, C. R., Herr, B. E. & Griggs, R. C. (1992). Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. Journal of the American Medical Association 267, 397399.
Freed, D. F. J., Banks, A. J., Longson, D. & Burley, D. M. (1975). Anabolic steroids in athletics: crossover double-blind trial on weightlifters. British Medical Journal 2, 471473.
Grunfeld, C. & Feingold, K. R. (1991). The metabolic effects of tumor necrosis factor and other cytokines. Biotherapy 3, 143158.
Grunfeld, C. & Feingold, K. R. (1992). Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. New England Journal of Medicine 327, 329337.
Hervey, G. R., Knibbs, A. V., Burkinshaw, L., ?Morgan, D. B., Jones, P. R., Chettle, D. R. & Vartsky, D. (1981). Effects of methandienone on the performance and body composition of men undergoing athletic training. Clinical Science 60, 457461.
Hommes, M. J. T., Romijn, J. A., Endert, E. & Sauerwein, H. P. (1991). Resting energy expenditure and substrate oxidation in human immunodeficiency virus (HIV)-infected asymptomatic men: HIV affects host metabolism in the early asymptomatic stage. American Journal of Clinical Nutrition 54, 311315.
Hughes, W. T., Price, R. A., Sisko, F., Havron, W. S., Kafatos, A. G., Schonland, M. & Smythe, P. M. (1974). Protein-calorie malnutrition: a host determinant for Pneumocystis carinii infection. American Journal of Diseases of Children 128, 4452.
Kochakian, C. D. (1976). Mechanism of action: regulation of protein synthesis by anabolic-androgenic steroids. In Anabolic-androgenic Steroids, pp. 211228 [Kochakian, C. D., editor]. New York: Springer.
Kotler, D. P., Tierney, A. R., Altilio, D., Wang, J. & Pierson, R. N. (1989a). Body mass repletion during ganciclovir therapy of cytomegalovirus infection in patients with the acquired immunodeficiency syndrome. Archives of Internal Medicine 149, 901905.
Kotler, D. P., Tierney, A. R., Brenner, S. K., Couture, S., Wang, J. & Pierson, R. N. Jr (1991). Preservation of short-term energy balance in clinically stable AIDS patients. American Journal of Clinical Nutrition 51, 1723.
Kotler, D. P., Tierney, A. R., Wang, J. & Pierson, R. N. (1989b). Magnitude of body cell-mass depletion and the timing of death from wasting in AIDS. American Journal of Clinical Nutrition 50, 444447.
Krentz, A. J., Koster, F. T., Crist, D. M., Finn, K., Johnson, L. Z., Boyle, P. J. & Schade, D. S. (1993). Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. Journal of the Acquired Immune Deficiency Syndrome 6, 245251.
Kupfer, S. R., Underwood, L. E., Baxter, R. C. & Clemmons, D. R. (1993). Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. Journal of Clinical Investigation 91, 391396.
Lahdvirta, J., Maury, C. P. J., Teppo, A. M. & Repo, H. (1988). Elevated levels of circulating cachectin/tumor necrosis factor in patients with acquired immunodeficiency syndrome. American Journal of Medicine 85, 289291.
Liebermann, S. A., Butterfield, G. E., Harrison, D. & Hoffman, A. R. (1993). Anabolic effects of recombinant insulin-like growth factor I in AIDS-associated cachexia. Proceedings of the 75th Annual Meeting of the Endocrine Society, 1664 Abstr.Bethesda:The Endocrine Society.
Loprinzi, C. L. (1992). Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clinics Proceedings 67, 11601162.
Loprinzi, C. L., Schaid, D. J., Dose, A. M., Burnham, N. L. & Jensen, M. D. (1993). Body-composition changes in patients who gain weight while receiving megestrol acetate. Journal of Clinical Oncology 11, 152154.
Macallan, D. C., Noble, C., Baldwin, C., Foskett, M., McManus, T. & Griffin, G. E. (1993). Prospective analysis of patterns of weight change in stage IV human immunodeficiency virus infection. American Journal of Clinical Nutrition 58, 417424.
Mayer, M. & Rosen, F. (1975). Interaction of anabolic steroids with glucocorticoid receptor sites in rat muscle cytosol. American Journal of Physiology 229, 13811386.
Micozzi, M. S., Albdnes, D., Jones, Y. & Chumlea, W. C. (1986). Correlations of body mass indices with weight, stature, and body composition in men and women in NHANES I and II. American Journal of Clinical Nutrition 44, 723731.
Mor, V., Laliberte, L., Morris, J. N. &; Wiemann, M. (1984). The Karnofsky performance status scale. Cancer 53, 20022007.
Mulligan, K., Grunfeld, C., Hellerstein, M. K., Neese, R. A. & Schambelan, M. (1993). Anabolic effects of recombinant human growth hormone in patients with wasting associated with human immunodeficiency virus infection. Journal of Clinical Endocrinology and Metabolism 71, 956962.
Navia, B. A., Jordan, B. D. & Price, R. W. (1986). The AIDS dementia complex. I. Clinical features. Annals of Neurology 19, 517524.
Oster, M. H., Enders, S. R., Samuels, S. J., Cone, L. A., Hooton, T. M., Browder, H. P. & Flvnn, N. M. (1994). Megestrol acetate in patients with AIDS and cachexia. Annals of Internal Medkine 121, 400408.
Patton, J. S., Shepard, H. M., Wilking, H., Lewis, G., Agganval, B. B., Eessalu, T. E., Gavin, L. A. & Grunfeld, C. (1986). Interferons and tumor necrosis factors have similar catabolic effects on 3T3 L1 cells. Proceedings of the National Academy of Sciences, USA 83, 83138317.
Probert, L., Keffer, J., Corbella, P., Cazlaris, H., Patsavoudi, E., Stephens, S. & Kaslaris, E. (1993). Wasting, ischemia, and lymphoid abnormalities in mice expressing T-cell targeted human tumor necrosis factor transgenes. Journal of Immunology 151, 18941906.
Reddy, M. M., Sorrell, S. J., Lange, M. & Grieco, M. H. (1988). Tumor necrosis factor and HIV p24 antigen levels in serum of HIV-infected populations. Journal of the Acquired Immune Deficiency Syndrome 1, 436440.
Schedel, I., Ballmaier, M., Rohde, F., Suttmann, U. & Deicher, H. (1994). Ketotifen inhibits tumor necrosis factor alpha production in the peripheral blood mononuclear cells of patients infected with human immunodeficiency virus. Journal of Interferon Research 14, 291292.
Shibuya, A., Ninomiya, N., Nakazawa, M., Nagasawa, t, Yoda, Y. & Abe, T. (1988). Oxymetholone therapy with familial antithrombin I11 deficiency. Thrombosis and Haemostasis 60, 495497.
Spitzer, W. O., Dobson, A. J., Hall, J., Chesterman, E., Levi, J., Shepherd, R. & Battista, R. N. (1981). Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. Journal of Chronic Diseases 34, 585597.
Turani, H., Levi, J., Zevin, D. & Kessler, E. (1983). Hepatic lesions in patients on anabolic androgenic therapy. Israel Journal of Medical Sciences 19, 332337.
Ullrich, R., Zeitz, M., Heise, W., L'age, M., Hofien, G. & Riecken, E. O. (1989). Small intestine function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Annals of Internal Medicine 111, 1521.
von Roenn, J. H., Armstrong, D., Kotler, D. P., Cohn, D. L., Klimas, N. G., Tchekmedyian, N. S., Cone, L., Brennan, P. J., & Weitzman, S. A. (1994). Megestrol acetate in patients with AIDS-related cachexia. Annals of Internal Medicine 121, 393399.
Welle, S., Jozefowicz, R., Forbes, G. & Griggs, R. C., (1992). Effect of testosterone on metabolic rate and body composition in normal men and men with muscular dystrophy. Journal of Clinical Endocrinology and Metabolism 74, 332335.
Williams-Ashman, H. G. (1971). Metabolic effects of testicular androgens. In Handbook of Physiology, section 3, vol. 5 [Green, R. O. and Astwood, E. G., editors]. Washington D. C.: American Physiological Society.
Williams, G., Ghatei, M., Burrin, J. & Bloom, S. (1986). Severe hyperglucagonaemia during treatment with oxymetholone. British Medical Journal 292, 16371638.

Keywords

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed